Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Study reveals key mechanism behind obesity-related metabolic dysfunction

Researchers found that feeding a high-fat diet (HFD) causes mitochondrial dysfunction and fragmentation in white adipocytes in mice.

31 Jan 2024

Enterprise Therapeutics closes £26 million ($33.1 million) Series B follow-on financing

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.

From Enterprise Therapeutics Ltd 31 Jan 2024

Liver fibrosis scores couldbe used for predicting adverse outcomes in patients with STEMI

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Liver fibrosis scores (LFSs) are novel tools for predicting cardiovascular events in patients with coronary artery disease.

29 Jan 2024

Study identifies risk factors for deadly blood clots after lung cancer surgery

In patients who undergo pulmonary resection for lung cancer, a major potential postoperative complication is venous thromboembolism (VTE)-;a condition that develops when a blood clot forms in a vein-;which can lead to part of the clot breaking off and lodging in the lung, resulting in a pulmonary embolism (PE).

29 Jan 2024

Mayo Clinic unveils "secret gene" key to reversing heart failure in some patients

Mayo Clinic researchers studying the genetics of people who had recently developed dilated cardiomyopathy, one of the most common causes of heart failure, have found a particular gene to target for developing future drug therapy treatments.

24 Jan 2024

Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases

Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, today announced their merger to form Calluna Pharma Inc. (Calluna).

From Calluna Pharma 24 Jan 2024

Dietary carotenoids may reduce risk of non-alcoholic fatty liver disease, study suggests

Study found no direct link between total dietary vitamin A intake and non-alcoholic fatty liver disease (NAFLD) risk, but observed an inverse correlation between provitamin A carotenoid consumption and NAFLD risk.

23 Jan 2024

3D-printed liver model paves way for new MASH treatments

Metabolic dysfunction- associated steatohepatitis, or MASH, is an inflammatory, liver-scarring disease that has reached epidemic proportions, with an estimated 1.5% to 6.5% of U.S. adults afflicted by the condition, and roughly 24% of adults having nonalcoholic fatty liver disease (NAFLD).

23 Jan 2024

Scientists identify a new approach to treating sarcoidosis

A research team led by Georg Stary (Medical University of Vienna and CeMM) has identified a new approach to treating the inflammatory disease sarcoidosis.

23 Jan 2024

Long COVID's impact on cardiovascular health: what we do and do not know

Researchers review the cardiovascular effects of long COVID.

23 Jan 2024

Cancer drug holds promise for shrinking polycystic kidney cysts

Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease, can lead to kidney enlargement and eventual loss of function.

22 Jan 2024

Aerobic exercise could help combat non-alcoholic fatty liver disease

According to a study conducted on animal models and published in the journal Metabolism, aerobic exercise could help fight the non-alcoholic fatty liver disease, the most common liver disease worldwide: it affects nearly 24% of the global population and it usually causes a certain stigma among the affected people.

22 Jan 2024

AI scores breakthrough in anemia treatment with novel PHD inhibitor

Clinical stage generative artificial intelligence (AI)-driven biotechnology company InSilico Medicine ("InSilico"), today announced that the Journal of Medicinal Chemistry, an ACS Publications journal focusing on critical studies about molecular structure and biological activity, has published the company's discovery of a novel PHD inhibitor for the treatment of anemia.

19 Jan 2024

Insilico Medicine leverages AI to identify promising new target for breast and gynecological cancers

Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven drug discovery company, recently published an early research that it has identified MYT1 as a promising new therapeutic target for breast and gynecological cancer, and discovered a series of novel, potent, and highly selective inhibitors specifically targeting MYT1.

19 Jan 2024

Groundbreaking study identifies FAM3C as a key regulator of breast cancer progression

A groundbreaking study conducted by Professor Jiyoung Park and her research team in the Department of Biological Sciences at UNIST has identified FAM3C, a metabolism-regulating signaling molecule produced by cancer-associated adipocytes (CAAs), as a key regulator of breast cancer progression within the tumor microenvironment (TME).

19 Jan 2024

The crucial need for ongoing COVID-19 booster vaccination in vulnerable populations

Researchers investigate the need for prioritizing COVID-19 booster vaccination.

19 Jan 2024

Morphine shows potential as effective cough therapy for pulmonary fibrosis, study finds

The efficacy of the controlled release of low-dose morphine as treatment against that of a placebo in idiopathic pulmonary fibrosis.

18 Jan 2024

TRPC3 emerges as key player in preventing damage from alcohol-associated liver disease

Excessive alcohol intake is strongly associated with alcohol-associated liver disease (ALD) which accounts for 25% and 30% of deaths from cirrhosis and hepatocellular carcinoma. Impairment of Ca2+ influx and Ca2+-mediated signaling in ALD suggests that Ca2+ channels are important in ALD pathological progression.

16 Jan 2024

£30M clinical study will enhance the understanding of NASH cirrhosis

The most extensive clinical study into liver cirrhosis ever conducted worldwide has been announced by Newcastle University, University of Edinburgh and leading research-driven global biopharmaceutical company, Boehringer Ingelheim.

8 Jan 2024

Comprehensive insights on pathophysiology and clinical management of atrial fibrillation

Atrial fibrillation (AF) is a major global health concern impacting millions and causing symptoms like palpitations, dyspnea, fatigue, dizziness, and chest discomfort.

8 Jan 2024

Fibrosis News and Research

Further Reading

Study reveals key mechanism behind obesity-related metabolic dysfunction

Enterprise Therapeutics closes £26 million ($33.1 million) Series B follow-on financing

Liver fibrosis scores couldbe used for predicting adverse outcomes in patients with STEMI

Study identifies risk factors for deadly blood clots after lung cancer surgery

Mayo Clinic unveils "secret gene" key to reversing heart failure in some patients

Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases

Dietary carotenoids may reduce risk of non-alcoholic fatty liver disease, study suggests

3D-printed liver model paves way for new MASH treatments

Scientists identify a new approach to treating sarcoidosis

Long COVID's impact on cardiovascular health: what we do and do not know

Cancer drug holds promise for shrinking polycystic kidney cysts

Aerobic exercise could help combat non-alcoholic fatty liver disease

AI scores breakthrough in anemia treatment with novel PHD inhibitor

Insilico Medicine leverages AI to identify promising new target for breast and gynecological cancers

Groundbreaking study identifies FAM3C as a key regulator of breast cancer progression

The crucial need for ongoing COVID-19 booster vaccination in vulnerable populations

Morphine shows potential as effective cough therapy for pulmonary fibrosis, study finds

TRPC3 emerges as key player in preventing damage from alcohol-associated liver disease

£30M clinical study will enhance the understanding of NASH cirrhosis

Comprehensive insights on pathophysiology and clinical management of atrial fibrillation

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News